Shanghai Ruikang Biotech and Thermo Fisher Scientific Strengthen Strategic Collaboration at the First International Forum on Laboratory Medicine
In early winter, under a blue sky with golden leaves, the 5th China International Import Expo opened as scheduled at the National Exhibition and Convention Center in Shanghai. Seizing this opportunity, the inaugural International Laboratory Medicine Summit Forum and In Vitro Diagnostics Industry Development Conference was grandly held on November 8.
Leaders from relevant national ministries and commissions, numerous Chinese and foreign academicians, renowned experts in the field of experimental medicine, and industry leaders convened to share cutting-edge scientific achievements in high-precision, advanced in vitro diagnostics and to jointly strategize on supporting the development of the “Healthy China 2030” initiative.
As the sole representative of China’s domestic mass spectrometry industry, Shanghai Ruikang Biotechnology Co., Ltd. was honored to be invited to attend and exhibit at the conference. Li Weiqi, Chairman of the Board, and Xie Xiaolei, Chief Scientist and Executive President of Shanghai Ruizhi Technology Co., Ltd., attended the event for exchange and learning. On the morning of the same day, a signing ceremony was held with Thermo Fisher Scientific to deepen their strategic partnership.
As a leader and frontrunner in clinical mass spectrometry, Shanghai Ruikang Biotechnology is committed to introducing high-quality, high-standard, highly automated, and compliant mass spectrometry products into the field of in vitro diagnostics for the benefit of the public. To date, multiple mass spectrometry products, ranging from instruments and consumables to reagents, have obtained Class II medical device registration certificates. Additionally, more than thirty Class I mass spectrometry-related reagents are available to meet clinical testing needs. Our comprehensive and flexible total solutions for clinical mass spectrometry will efficiently address the pain points and challenges associated with its clinical application.
Against the national backdrop advocating for precision testing and precision treatment, mass spectrometry holds an irreplaceable position. As the industry-recognized gold standard, it is bound to fulfill its essential role in clinical diagnostics. Shanghai Ruikang Bio will continue to devote itself to in-depth development in the field of clinical mass spectrometry, pursuing steady progress and long-term goals, thereby making its due contribution to the cause of precision diagnostics.
